Welcome to our dedicated page for AZYO news (Ticker: AZYO), a resource for investors and traders seeking the latest updates and insights on AZYO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AZYO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AZYO's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aziyo Biologics, Inc. (Nasdaq: AZYO) has entered into a three-year exclusive distribution agreement with LeMaitre Vascular, Inc. (Nasdaq: LMAT) for its cardiovascular products including ProxiCor PC, ProxiCor CTR, Tyke, and VasCure. This partnership aims to enhance the operational efficiency of Aziyo, allowing them to focus on their CanGaroo Envelope product, designed to reduce complications from implantable devices. The agreement provides LeMaitre the option to acquire the product line after the first year. Aziyo's offerings utilize an extracellular matrix derived from porcine small intestine submucosa, known for improving healing and reducing inflammation. The collaboration seeks to expand the availability of these products in the U.S. market.